Dual Energy X-ray Absorptiometry (DXA)] in all men aged ≥70 years and all women aged ≥65 years Consider BMD assessment in men and women ≥50 years old if intermediate to high FRAX score and/or additional risk factors Anti-HBs, anti-hepatitis B virus surface antibody; anti-HBc, anti-hepatitis B virus core total antibody;
BMD, bone mineral density; BMI, body mass index; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; FBC, full blood count; HBsAg, hepatitis B virus surface antigen; HCV, hepatitis C virus; IDUs, injecting drug users; LFT, liver function test; MSM, men who have sex with men; STIs, sexually transmitted infections. Within 3 months prior to commencing ART. History Adherence evaluation
Medication history Crizotinib Over-the-counter, recreational drug use Examination Weight, blood pressure, BMI Waist circumference Investigations FBC Creatinine, eGFR, LFTs, glucose, lipid profile, bone profile Urinalysis Urine protein/creatinine ratio CD4 T-cell count HIV-1 plasma viral load HLA B*5701 testing (if considering use of abacavir) Tropism testing [if considering use of chemokine (C-C motif) receptor PARP cancer 5 (CCR5) antagonist – alternatively consider storing plasma sample for future testing] All patients should have their HBV and HCV status reviewed and an assessment undertaken of whether repeat testing is indicated or not Assessment CVD risk Fracture risk assessment in
patients aged ≥50 years ART, antiretroviral therapy; BMI, body mass index; CCR5, chemokine (C-C motif) receptor 5; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; FBC, full blood count; HBV, hepatitis B virus; HCV, hepatitis C virus; HLA, human leucocyte antigen; LFT, liver function test. Patients should be assessed within 2–4 weeks of commencing ART. Time of assessment within this range will be influenced ZD1839 cost by factors including the regimen selected (see text). History Side effects Adherence Investigations FBC Creatinine, eGFR, LFTs, glucose, bone profile CD4 T-cell count (4 weeks) HIV-1 plasma viral load (4 weeks) ART, antiretroviral therapy; eGFR, estimated glomerular filtration rate; FBC, full blood count; LFT, liver function test. Individuals with good adherence and full virological suppression should be assessed 3–6-monthly. More frequent assessment will be required if patients are not fully suppressed or other problems present.